Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)

References

• AbramsPSchulmanCCVaageSTamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). The European Tamsulosin Study GroupBr J Urol199576325367551841
   PubMedGoogle Scholar
• AbramsPSpeakmanMStottMA dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia)Br J Urol199780587969352698
   PubMedGoogle Scholar
• [ALLHAT] ALLHAT Collaborative Research GroupMajor cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research GroupJAMA200028319677510789664
   PubMed Web of Science ®Google Scholar
• AnderssonKEChappleCRHofnerKFuture drugs for the treatment of benign prostatic hyperplasiaWorld J Urol2002194364212022712
   PubMed Web of Science ®Google Scholar
• AnderssonKELeporHWyllieMGProstatic alpha 1-adrenoceptors and uroselectivityProstate199730202159122046
   PubMed Web of Science ®Google Scholar
• AnderssonKEStiefCGNeurotransmission and the contraction and relaxation of penile erectile tissuesWorld J Urol19971514209066089
   PubMed Web of Science ®Google Scholar
• BarrowJCNantermetPGSelnickHGIn vitro and in vivo evaluation of dihydropyrimidinone c-5 amides as potent and selective receptor antagonists for the treatment of benign prostatic hyperplasiaJ Med Chem20004327031810893308
   PubMed Web of Science ®Google Scholar
• BarryMJFowlerFJJr.O’LearyMPThe American Urological Association symptom index for benign prostatic hyperplasiaJ Urol19921481549571279218
   PubMed Web of Science ®Google Scholar
• BarryMJFowlerFJJr.O’LearyMPMeasuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological AssociationMed Care199533AS145557536866
   PubMed Web of Science ®Google Scholar
• BeckerAJStiefCGMachtensSOral phentolamine as treatment for erectile dysfunctionJ Urol19981591214169507837
   PubMed Web of Science ®Google Scholar
• BeckerAJUckertSStiefCGCavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy men and patients with erectile dysfunctionUrology200259281611834403
   PubMed Web of Science ®Google Scholar
• BentSKaneCShinoharaKSaw palmetto for benign prostatic hyperplasiaN Engl J Med20063545576616467543
   PubMed Web of Science ®Google Scholar
• BerrySJCoffeyDSWalshPCThe development of human benign prostatic hyperplasia with ageJ Urol198413247496206240
   PubMed Web of Science ®Google Scholar
• BerthelsonSPWA functional basis for the classification of alpha adrenergic receptorLife Sci19772159560020542
   PubMed Web of Science ®Google Scholar
• BoyarskySJonesGPaulsonDFA new look at bladder neck obstruction by the food and drug administration regulators: guide lines for investigation of benign prostatic hypertrophyTrans Am Assoc Genitourin Surg197668293271777
   PubMedGoogle Scholar
• BruskewitzRGirmanCJFowlerJEffect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasiaUrology199954670810510926
   PubMed Web of Science ®Google Scholar
• CaineMThe present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophyJ Urol1986136142423716
   PubMed Web of Science ®Google Scholar
• CaineMPerlbergSMeretykSA placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstructionBr J Urol197850551488984
   PubMedGoogle Scholar
• CaineMPfauAPerlbergSThe use of alpha-adrenergic blockers in benign prostatic obstructionBr J Urol1976482556361054
   PubMedGoogle Scholar
• CarboneDJJr.HodgesSMedical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of lifeInt J Impot Res20031529930612934061
   PubMed Web of Science ®Google Scholar
• CarraroJCRaynaudJPKochGComparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patientsProstate19962923140 discussion 241–28876706
   PubMed Web of Science ®Google Scholar
• ChappleCRCarterPChristmasTJA three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstructionBr J Urol1994745067519112
   PubMedGoogle Scholar
• ChappleCRWyndaeleJJNordlingJTamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study GroupEur Urol199629155678647141
   PubMed Web of Science ®Google Scholar
• ChatelainCAutetWBrackmanFComparison of once and twice daily dosage forms of P extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extensionUrology199954473810475357
   PubMed Web of Science ®Google Scholar
• ChungMVashiVPuenteJClinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulationBr J Clin Pharmacol1999486788710594469
   PubMed Web of Science ®Google Scholar
• CockettATAsoYDenisLWorld Health Organization Consensus Committee recommendations concerning the diagnosis of BPHProg Urol19911957721726946
   PubMedGoogle Scholar
• CoffeyDSWalshPCClinical and experimental studies of benign prostatic hyperplasiaUrol Clin North Am199017461751695775
   PubMed Web of Science ®Google Scholar
• de ReijkeTMKlarskovPComparative efficacy of two alpha-1 adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargementBJU International2004937576215049986
   PubMed Web of Science ®Google Scholar
• DebruyneFBoylePCalais Da SilvaFEvaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysisEur Urol2004457739 disucssion 779–8015149751
   PubMed Web of Science ®Google Scholar
• DebruyneFKochGBoylePComparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international studyEur Urol200241497506 discussion 506–712074791
   PubMed Web of Science ®Google Scholar
• DjavanBMarbergerMA meta-analysis on the efficacy and tolerability of a 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstructionEur Urol19993611310364649
   PubMed Web of Science ®Google Scholar
• ElhilaliMMRamseyEWBarkinJA multicenter, randomized, double-blind, placebocontrolled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasiaUrology199647335428633398
   PubMed Web of Science ®Google Scholar
• FawzyABraunKLewisGPDoxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter studyJ Urol199515410597539853
   PubMed Web of Science ®Google Scholar
• FoglarRShibataKHorieKUse of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophyEur J Pharmacol199528820177536677
   PubMed Web of Science ®Google Scholar
• FongYKMilaniSDjavanBNatural history and clinical predictors of clinical progression in benign prostatic hyperplasiaCurr Opin Urol2005a1535815586028
   PubMed Web of Science ®Google Scholar
• FongYKMilaniSDjavanBRole of phytotherapy in men with lower urinary tract symptomsCurr Opin Urol2005b1545815586030
   PubMed Web of Science ®Google Scholar
• ForrayCBardJAWetzelJMThe alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtypeMol Pharmacol19944570388183249
   PubMed Web of Science ®Google Scholar
• FowlerFJJr.WennbergJETimothyRPSymptom status and quality of life following prostatectomyJAMA19882593018222452905
   PubMed Web of Science ®Google Scholar
• FrankelSJDonovanJLPetersTISexual dysfunction in men with lower urinary tract symptomsJ Clin Epidemiol199851677859743316
   PubMed Web of Science ®Google Scholar
• GerberGSKuznetsovDJohnsonBCRandomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptomsUrology2001589604 discussion 964–511744467
   PubMed Web of Science ®Google Scholar
• GillenwaterJYConnRLChrysantSGDoxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter studyJ Urol1995154110157539854
   PubMed Web of Science ®Google Scholar
• GormleyGJStonerEBruskewitzRCThe effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study GroupN Engl J Med19923271185911383816
   PubMed Web of Science ®Google Scholar
• GuayDRPExtended-release alfuzosin hydrochloride: A new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasiaAm J Geriatr Pharmacother20042142315555475
   PubMedGoogle Scholar
• GwinupGOral phentolamine in nonspecific erectile insufficiencyAnn Intern Med198810916233382107
   PubMed Web of Science ®Google Scholar
• HaldTNordlingJAndersenJTA patient weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasiaScand J Urol Nephrol Suppl199113859621723812
   PubMedGoogle Scholar
• HedlundHAnderssonKEEkAEffects of prazosin in patients with benign prostatic obstructionJ Urol198313027586192252
   PubMed Web of Science ®Google Scholar
• HöfnerKClaesHDe ReijkeTMTamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstructionEur Urol1999363354110473995
   PubMed Web of Science ®Google Scholar
• IshaniAMacDonaldRNelsonDPygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysisAm J Med20001096546411099686
   PubMed Web of Science ®Google Scholar
• JacobsenSJJacobsonDJGirmanCJNatural history of prostatism: risk factors for acute urinary retentionJ Urol199715848179224329
   PubMed Web of Science ®Google Scholar
• JenkinsEPAnderssonSImperato-McGinleyJGenetic and pharmacological evidence for more than one human steroid 5 alpha-reductaseJ Clin Invest1992892933001345916
   PubMed Web of Science ®Google Scholar
• [JNC] Joint National CommitteeThe sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressureArch Intern Med19971572413469385294
   PubMedGoogle Scholar
• KellyJPKaufmanDWKelleyKRecent trends in use of herbal and other natural productsArch Intern Med2005165281615710790
   PubMed Web of Science ®Google Scholar
• KirbyRSEfficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasiaScand J Urol Nephrol Suppl199516829337541549
   PubMedGoogle Scholar
• KirbyRSAndersenMGratzkePA combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasiaBJU Int20018719220011167641
   PubMed Web of Science ®Google Scholar
• KirbyRSRoehrbornCBoylePEfficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trialUrology2003611192612559281
   PubMed Web of Science ®Google Scholar
• LeporHRole of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasiaUrol Clin North Am19901765191695785
   PubMed Web of Science ®Google Scholar
• LeporHLong-term efficacy and safety of terazosin in patients with benign prostatic hyperplasiaUrology199545406137533452
   PubMed Web of Science ®Google Scholar
• LeporHPhase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasiaUrology1998518929009609623
   PubMed Web of Science ®Google Scholar
• LeporHKaplanSAKlimbergIDoxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study GroupJ Urol1997157525308996348
   PubMed Web of Science ®Google Scholar
• LeporHWillifordWOBarryMJThe efficacy of terazosin, finasteride, or both in benign prostatic hyperplasiaN Engl J Med1996335533408684407
   PubMed Web of Science ®Google Scholar
• LoweFCTreatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual functionBJU International200595121815871731
   PubMed Web of Science ®Google Scholar
• LoweFCFagelmanEPhytotherapy in the treatment of benign prostatic hyperplasia: an updateUrology199953671810197839
   PubMed Web of Science ®Google Scholar
• LukacsBLeplegeAThibaultPProspective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year resultsUrology199648731408911517
   PubMed Web of Science ®Google Scholar
• MacDonaldDMcNicholasTADrug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of lifeDrugs20036319476212930164
   PubMed Web of Science ®Google Scholar
• MacDonaldRWiltTJAlfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: A systematic review of efficacy and adverse effectsUrology200566780816230138
   PubMed Web of Science ®Google Scholar
• MacfarlaneGJBottoHSagnierPPThe relationship between sexual life and urinary condition in the French communityJ Clin Epidemiol199649117168826998
   PubMed Web of Science ®Google Scholar
• MadsenPIversenPA point system for selecting operative candidates1983New YorkSpringer-Verlag
   Google Scholar
• McAlisterFALaupacisAWellsGAUsers’ Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effectJAMA19992821371710527185
   PubMed Web of Science ®Google Scholar
• McConnellJDMedical management of benign prostatic hyperplasia with androgen suppressionProstate Suppl1990349591689170
   PubMedGoogle Scholar
• McConnellJDBruskewitzRWalshPThe effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study GroupN Engl J Med1998338557639475762
   PubMed Web of Science ®Google Scholar
• McConnellJDRoehrbornCGBautistaOMThe long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaN Engl J Med200334923879814681504
   PubMed Web of Science ®Google Scholar
• MeyhoffHHHaldTNordlingJA new patient weighted symptom score system (DAN-PSS-1). Clinical assessment of indications and outcomes of transurethral prostatectomy for uncomplicated benign prostatic hyperplasiaScand J Urol Nephrol19932749397512748
   PubMed Web of Science ®Google Scholar
• MullanRJBergstralhEJFarmerSAGrowth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of menUrology200667300516461080
   PubMed Web of Science ®Google Scholar
• NarayanPEvansCPMoonTLong-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasiaJ Urol200317049850212853808
   PubMed Web of Science ®Google Scholar
• NarayanPTewariAA second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93–01 Study GroupJ Urol1998160170169783935
   PubMed Web of Science ®Google Scholar
• NordlingJEfficacy and safety of two doses (10 and 15mg) of alfuzosin or tamsulosin (0.4mg) once daily for treating symptomatic benign prostatic hyperplasiaBJU Int20059510061215839922
   PubMed Web of Science ®Google Scholar
• O’LearyMPRoehrbornCAndrioleGImprovements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5-reductase inhibitorBJU Int200392262612887480
   PubMed Web of Science ®Google Scholar
• OkJHCambioALaraPNIs the use of anything but MVAC justified in the evidence-based medicine era?Curr Opin Urol2005153121416093854
   PubMed Web of Science ®Google Scholar
• PalacioAHernandezCMarquesALong-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up reportArch Esp Urol2004574516015270291
   PubMedGoogle Scholar
• PetersCAWalshPCThe effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasiaN Engl J Med19873175996042441256
   PubMed Web of Science ®Google Scholar
• RhodesPRKroghRHBruskewitzRCImpact of drug therapy on benign prostatic hyperplasia-specific quality of lifeUrology1999531090810367833
   PubMed Web of Science ®Google Scholar
• RhodesTGirmanCJJacobsenSJLongitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years oldJ Urol19991611174910081864
   PubMed Web of Science ®Google Scholar
• RichardsonCDDonatucciCFPageSOPharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypesProstate1997335599294627
   PubMed Web of Science ®Google Scholar
• RobertsROBergstralhEJFarmerSAPolymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasiaThe Prostate20066639240416302261
   PubMed Web of Science ®Google Scholar
• RobertsROJacobsenSJJacobsonDJLongitudinal changes in peak urinary flow rates in a community based cohortJ Urol20001631071310604326
   PubMed Web of Science ®Google Scholar
• RobertsROLieberMMJacobsonDJLimitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the communityMayo Clin Proc2005807596415948299
   PubMed Web of Science ®Google Scholar
• RoehrbornCGBoylePNickelJCEfficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaUrology2002604344112350480
   PubMed Web of Science ®Google Scholar
• RoehrbornCGLukkarinenOMarkSLong-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5 alpha-reductase inhibitor dutasteride: results of 4-year studiesBJU Int200596572716104912
   PubMed Web of Science ®Google Scholar
• RoehrbornCGMaliceMPCookTJClinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trialsUrology2001582101611489703
   PubMed Web of Science ®Google Scholar
• RoehrbornCGOesterlingJEAuerbachSThe hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasiaUrology199647159688607227
   PubMed Web of Science ®Google Scholar
• RoehrbornCGSchwinnDAAlpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasiaJ Urol200417110293514767264
   PubMed Web of Science ®Google Scholar
• RoehrbornCGVan KerrebroeckPNordlingJSafety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studiesBJU Int2003922576112887479
   PubMed Web of Science ®Google Scholar
• RuleADJacobsonDJMcGreeMELongitudinal changes in post-void residual and voided volume among community dwelling menJ Urol2005174131721, discussion 1321–2, author reply 132216145411
   PubMed Web of Science ®Google Scholar
• SarmaAVJacobsenSJGirmanCJConcomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling menJ Urol200216814465212352415
   PubMed Web of Science ®Google Scholar
• SchulmanCCLockTMBuzelinJMLong-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasiaJ Urol200116613586311547074
   PubMed Web of Science ®Google Scholar
• SmithTJSomerfieldMRThe ASCO experience with evidence-based clinical practice guidelinesOncology (Williston Park)19971122379430192
   PubMedGoogle Scholar
• StachonASchluterTJunkerKThe secretion of endothelin-1 by microvascular endothelial cells from human benign prostatic hyperplasia is inhibited by vascular endothelial growth factorGrowth Factors200422281915621731
   PubMed Web of Science ®Google Scholar
• ThigpenAESilverRIGuileyardoJMTissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expressionJ Clin Invest199392903107688765
   PubMed Web of Science ®Google Scholar
• VallancienGEmbertonMHarvingNSexual dysfunction in 1,274 European men suffering from lower urinary tract symptomsJ Urol200316922576112771764
   PubMed Web of Science ®Google Scholar
• van MoorselaarRJHartungREmbertonMAlfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunctionBJU Int200595603815705088
   PubMed Web of Science ®Google Scholar
• VerhammeKMCDielemanJPBleuminkGSTreatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph ProjectEur Urol2003445394514572751
   PubMed Web of Science ®Google Scholar
• VermeulenAGiagulliVADe SchepperPHormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humansProstate19891445532538808
   PubMed Web of Science ®Google Scholar
• WalshPCRetikABVaughanEDCampbell’s Urology20028th edPhiladelphiaWB Saunders
   Google Scholar
• WeiJTCalhounEJacobsenSJUrologic diseases in America project: benign prostatic hyperplasiaJ Urol200517312566115758764
   PubMed Web of Science ®Google Scholar
• WrightEJFangJMetterEJProstate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of AgingJ Urol200216724847 discussion 2487–811992063
   PubMed Web of Science ®Google Scholar
• WyllieMGEvergreening: there’s life in the old drug yetBJU Int20059513596015892830
   PubMed Web of Science ®Google Scholar